Additionally, an AAV-mediated ApoE2 expression vector targeting the ApoE4 gene of AD patients to transform the ApoE4 homozygote to an ApoE2-ApoE4 heterozygote for treating AD is currently in clinical trials [117]. The gene discussed is APOE; the disease is Alzheimer disease.